By: Dr. Anam Kamal Ascension Providence Hospital; Michigan The standard of care for such patients is platinum-based doublet chemotherapy. In…
By Dr. Kanak Parmer Texas Tech University Health Sciences Center On October 16,2023 the U.S. Food and Drug Administration…
MARIPOSA-2: A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal…
By Dr. Anam Kamal Ascension Providence Hospital TROPION-Lung01: A randomized, phase-3 study of datopotamab deruxtecan (Dato-DXd; DS-1062) versus docetaxel in…
ESMO 2023 Update - KEYNOTE-671: The First Perioperative Immunotherapy Clinical Trial in Non-Small Cell Lung Cancer Improving Overall Survival Author:…
ESMO 2023 Update – MARIPOSA: Amivantamab + Lazertinib Improves Progression-Free Survival Compared to Osimertinib in EGFR-Mutated, Treatment-Naïve Non-Small Cell Lung…
ESMO 2023 Update – ALINA: Adjuvant Alectinib Improves Disease-Free Survival in Resected Early-Stage Non-Small Cell Lung Cancer Author: Lei Deng,…
ESMO 2023 Update – CheckMate 77T: Another Phase 3 Trial of Perioperative Immunotherapy Improving Event-Free Survival for Resectable Stage II-III…
By Dr. Aakash Desai Mayo Clinic KEYNOTE-789: No Significant Efficacy Benefit with Addition of Pembrolizumab to Chemotherapy in TKI-Resistant,…
Author: Lei Deng, MD Roswell Park Comprehensive Cancer Center Live report from ASCO23, Chicago, IL June 6, 2023 …